MGM New Bombay Hospital, located in Vashi, Navi Mumbai, has been providing medical services since 1989 as a not-for-profit, multispecialty healthcare institution. Serving Navi Mumbai and the Raigad district, it has grown into a 400-bedded hospital delivering tertiary care across clinical disciplines while maintaining a trust-based service model rather than a corporate healthcare structure.
Over the years, MGM has developed specialised facilities in oncology, organ transplantation, chemotherapy and radiotherapy, supported by advanced medical equipment and robotic surgery. Its clinical expansion has been guided by functional requirements rather than market positioning, with emphasis placed on integrating technology into established treatment protocols rather than adopting it for visibility alone.
Diagnostics play a central role in MGM’s clinical workflow rather than functioning as an auxiliary service. The hospital’s NABL-accredited laboratories support decision-making in oncology, hematology, prenatal medicine and genetics, contributing to MGM’s emergence as a referral centre for complex diagnostic cases in western India.
The hospital has consciously positioned diagnostic accuracy as a determinant of clinical outcomes, particularly in areas where treatment protocols depend heavily on laboratory interpretation.
Institutional Standards and Accreditation
MGM’s operational credibility is supported by sustained accreditation. The hospital has held NABH accreditation since 2015, while its diagnostic laboratories have been NABL accredited since 2011. In 2021, MGM also achieved Joint Commission International (JCI) accreditation, placing it among Indian hospitals aligned with global standards of patient safety, quality assurance and clinical governance.
These accreditations are reflected in structured internal processes, including clinical audits, infection control systems, traceability in diagnostics and continuous quality monitoring.
Ethical Operating Framework
MGM has maintained a clear policy against referral incentives and commission-based practices. Genetic diagnostic services are offered at cost-to-cost pricing, with full charity extended to deserving patients. This ethical framework has helped establish the hospital as a credible referral destination based on clinical trust rather than financial alignment.
Current Focus and Future Direction
MGM’s genetics services have historically centred on clinical cytogenetics and FISH-based diagnostics. Dr. Ganguly is now guiding the centre toward molecular genetics and mutation-based diagnostics, particularly for prevalent heritable diseases and cancer therapy monitoring. A visit to European LeukemiaNet institutions is planned in 2026 to support this transition.
